Innoplexus CEO: blockchain will 'bring down the consumer price of drugs'

blockchain_network_big

For several years, pharma analysts have predicted varying degrees of impact from nascent blockchain technologies.

While some suggest wholesale revolution is in the offing, others anticipate more incremental evolution for a conservative industry that is traditionally resistant to change.

Most commonly associated with cyptocurrencies such as Bitcoin, a blockchain is a transparent, publically maintained ledger of transactions - a simple idea that unlocks a range of potentially transformative applications for businesses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical